Nebivolol hydrochloride is a selective β1- antagonist falls under class II biopharmaceutical classification system. In the present investigation liquisolid compaction approach is applied to improve the dissolution and permeability properties thereby enhancing the oral bioavailability of nebivolol hydrochloride. Different formulations were developed by dissolving the drug in mixture of Transcutol HP & Propylene glycol (Non volatile liquid; 1:1 ratio), converting this liquid medication using fujicalin and neusilin as carriers and syloid FP 244 as coating material. In vitro drug release profiles of liquisolid compacts shown enhanced drug release when compared to pure drug as well as marketed formulation. The plasma concentration-time profile of healthy wister rats indicated that the oral bioavailability of optimized formulation has been significantly improved when compared to pure drug and marketed formulation. Improved bioavailability might be due to increased wetting properties of drug and improved permeability of the drug due to lipophilic properties of solvent used for wetting. From this study we can conclude that liquisolid technique is one of the promising alternative techniques to improve the bioavailability of class II drugs.